Bladder Cancer Clinical Trial
Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay
Summary
The AnchorDx UriFindâ„¢ Bladder Cancer Assay is designed to detect 2 DNA methylation biomarkers in urine specimens from patients 22 years or older suspected of having bladder cancer. Results from the assay are intended for use, in conjunction with current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients.
Eligibility Criteria
Inclusion Criteria:
Clinical Validation Group:
55 years or older, gender is not limited
Suspected of bladder cancer and are scheduled for bladder biopsy or trans-uretheral resection of bladder tumor (TUBRT)
Can receive standard of care, including urine cytology, cystoscopy, or surgery for bladder cancer diagnosis
Can provide at least of 75 ml of urine (prior to cystoscopy or surgery)
Exclusion Criteria:
History of urinary cancer
Neoadjuvant therapy
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 2 Locations for this study
How clear is this clinincal trial information?